Instrument Inactif

Communiqués Peptonic Medical AB Nasdaq Stockholm

Actions

Cours en clôture Nasdaq Stockholm Autres places de cotation
- ^SEK	-

31/05	Peptonic Medical AB obtient un brevet en Europe pour le soulagement de la vulvodynie provoquée chez les femmes, le produit est prêt à être lancé	CI
21/05	Peptonic Medical AB annonce des changements organisationnels	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Peptonic Medical: Peptonic announces outcome in the rights issue and the directed issue	14/06	PU
Peptonic announces outcome in the rights issue and the directed issue	14/06	AQ
Peptonic Medical provides an operational update after the first 120 days with new CEO	11/06	AQ
Last day of trading with the unit rights in Peptonic	07/06	AQ
Peptonic Medical AB granted patent in Europe for relief of provoked vulvodynia in women. Product ready for launch.	31/05	AQ
The subscription period in Peptonic's rights issue of units starts today	28/05	AQ
Peptonic publishes prospectus in connection with rights issue of units	24/05	AQ
PEPTONIC medical : Interim report Jan-March 2024	23/05	PU
Peptonic Medical AB Announces Organizational Changes	21/05	AQ
The board of Peptonic has decided to carry out a directed issue of units consisting of shares and warrants of series TO5	19/05	AQ
PEPTONIC medical : Updated year end report Jan-Dec 2023	16/05	PU
PEPTONIC medical : Year end report Jan Dec 2023	16/05	PU
Jenni Björnulfson appointed as new CFO of Peptonic Medical	15/05	AQ
Warrants of series TO4 were subscribed to approximately 1.80 percent and Peptonic receives approximately SEK 0.1 million	07/05	AQ
The last day of trading with the warrants of series TO4 in PEPTONIC medical AB is today, April 26, 2024	26/04	AQ
The board of Peptonic resolves, subject to approval of the general meeting, on a rights issue of units of approximately SEK 61.4 million	16/04	AQ
The subscription price for the warrants of series TO4 in PEPTONIC medical AB has been determined to SEK 0.028 and the exercise period starts April 17, 2024	16/04	AQ
Peptonic Medical AB granted patent in the USA for treatment and prevention of yeast infections among women	15/04	AQ
Peptonic Medical AB strengthens its position in Europe through an exclusive distribution agreement for VagiVital and Vernivia in the Benelux region	02/04	AQ
Peptonic Medical AB announces that CFO is leaving for new challenges and that the company's financial infrastructure is strengthened	28/03	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Peptonic Medical AB Nasdaq Stockholm

Actions

Communiqués

Filtres